87 related articles for article (PubMed ID: 3480699)
1. [Pharmacokinetic study of aclarubicin. The pharmacokinetics of the preparation and its biologically active metabolites in the blood of rats].
Geodakian SV; Firsov AA; Fomina IP
Antibiot Med Biotekhnol; 1987 Oct; 32(10):768-72. PubMed ID: 3480699
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic study of aclarubicin. The distribution of the preparation and its biologically active metabolites in rat tissues].
Firsov AA; Geodakian SV; Egorov LV; Terent'eva TG
Antibiot Med Biotekhnol; 1987 Oct; 32(10):773-7. PubMed ID: 3480700
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetic validation of the antitumor efficacy of aclarubicin administered by various routes in CBF1 mice with Ca 755 carcinoma].
Viadro MM; Firsov AA; Terent'eva TG; Kashina LB
Eksp Onkol; 1989; 11(4):74-6. PubMed ID: 2759016
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin-A (Aclarubicin).
Kerr IG; Archer S; DeAngelis C; Farrell S; Hanna S; McKee J
Invest New Drugs; 1987; 5(2):171-6. PubMed ID: 3477533
[TBL] [Abstract][Full Text] [Related]
5. [Action of the antitumor antibiotic aclarubicin on the blood system and bone marrow hematopoiesis in an experiment].
Svinogeeva TP
Antibiot Med Biotekhnol; 1987 Dec; 32(12):915-9. PubMed ID: 3481540
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of aclarubicin and its metabolites in humans and their disposition in blood cells.
Ando S; Nakamura T; Kagawa D; Ueda T; Nishimura T; Kubo A; Tsutani H; Sasada M; Uchino H
Cancer Treat Rep; 1986 Jul; 70(7):835-41. PubMed ID: 3459574
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunoassay for aclacinomycin A.
Matsuzawa Y; Kiyosaki T; Oki T; Takeuchi T; Umezawa H
Gan; 1982 Apr; 73(2):229-33. PubMed ID: 6956531
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after i.v. bolus multiple administration in rats.
Yoo BI; Ahan KB; Kang MH; Kwon OS; Hong YS; Lee JJ; Lee HS; Ryu JS; Kim TY; Moon DC; Song S; Chung YB
Arch Pharm Res; 2005 Apr; 28(4):476-82. PubMed ID: 15918523
[TBL] [Abstract][Full Text] [Related]
9. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
10. Oral and intravenous trichloroethylene pharmacokinetics in the rat.
D'Souza RW; Bruckner JV; Feldman S
J Toxicol Environ Health; 1985; 15(5):587-601. PubMed ID: 4046066
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics of the new antitumor antibiotic reumycin in an experiment: the prediction of the human pharmacokinetic profiles].
Firsov AA; Geodakian SV; Terent'eva TG; Fomina IP
Antibiot Med Biotekhnol; 1985 Apr; 30(4):296-301. PubMed ID: 4026251
[TBL] [Abstract][Full Text] [Related]
12. [Studies on the absorption, excretion and distribution of aclacinomycin A: absorption, excretion and distribution of aclacinomycin A in mice, rabbits and dogs by photometric assay (author's transl)].
Iguchi H; Matsushita Y; Ohmori K; Hirano S; Kiyosaki T; Hori S; Tone H; Oki T
Jpn J Antibiot; 1980 Feb; 33(2):179-91. PubMed ID: 6929360
[TBL] [Abstract][Full Text] [Related]
13. Sensitive enzyme immunoassay for the quantification of aclacinomycin A using beta-D-galactosidase as a label.
Sohda M; Fujiwara K; Saikusa H; Kitagawa T; Nakamura N; Hara K; Tone H
Cancer Chemother Pharmacol; 1985; 14(1):53-8. PubMed ID: 3917377
[TBL] [Abstract][Full Text] [Related]
14. Experimental and clinical studies on aclarubicin in the treatment of solid tumors.
Kumai K; Kubota T; Ishibiki K; Abe O
Biomed Pharmacother; 1984; 38(7):332-7. PubMed ID: 6596963
[TBL] [Abstract][Full Text] [Related]
15. [Experimental study of the antitumor anthracycline antibiotic aclarubicin (aclacinomycin A)].
Egorov LV; Terent'eva TG; Rudneva NA; Egorenko GG; Ivanitskaia LP
Antibiot Med Biotekhnol; 1985 Dec; 30(12):918-27. PubMed ID: 3866512
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of doxorubicin, (2"R)-4'-O-tetrahydropyranyl-adriamycin and aclarubicin.
Fujita H; Ogawa K; Tone H; Iguchi H; Shomura T; Murata S
Jpn J Antibiot; 1986 May; 39(5):1321-36. PubMed ID: 3463778
[TBL] [Abstract][Full Text] [Related]
17. [Clinical pharmacokinetics of the antitumor antibiotic reumycin: an analysis of individual variability].
Firsov AA; Geodakian SV; Lichinitser MR; Shutka VIa
Antibiot Med Biotekhnol; 1985 Aug; 30(8):604-8. PubMed ID: 4062279
[TBL] [Abstract][Full Text] [Related]
18. Preliminary pharmacokinetics of a new pyridopyrimidine derivative.
Pérez MJ; Roch MJ; Ochoa MC
Arzneimittelforschung; 1991 Jun; 41(6):640-4. PubMed ID: 1930354
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of intravenous and oral idarubicin in cancer patients.
Tamassia V; Pacciarini MA; Moro E; Piazza E; Vago G; Libretti A
Int J Clin Pharmacol Res; 1987; 7(5):419-26. PubMed ID: 3478310
[TBL] [Abstract][Full Text] [Related]
20. [Modelling of rifampicin pharmacokinetics in experimental animals administered the drug intravenously and internally].
Firsov AA; Umnova LV; Stepanov VM; Fomina IP
Antibiot Med Biotekhnol; 1986 Jun; 31(6):445-9. PubMed ID: 3740826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
